Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriCalm is a topical hydrogel formulation containing strontium nitrate as its active ingredient, specifically developed to alleviate pruritus (itching), burning, and stinging. Unlike traditional anti-itch treatments that utilize steroids or antihistamines, TriCalm employs strontium ions to selectively inhibit the firing of type C nociceptors, which are the sensory nerve fibers responsible for transmitting itch and pain signals from the skin to the central nervous system. This non-steroidal approach provides rapid relief for various dermatological conditions. TriCalm is currently being evaluated in clinical trials, notably by the University of California, San Diego, for the management of immunotherapy-related pruritus in patients treated with immune checkpoint inhibitors (ICIs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TriCalm.